Literature DB >> 17574979

Spatial heterogeneity of low-grade gliomas at the capillary level: a PET study on tumor blood flow and amino acid uptake.

Matthias T Wyss1, Silvia Hofer, Martin Hefti, Esther Bärtschi, Catrina Uhlmann, Valerie Treyer, Ulrich Roelcke.   

Abstract

UNLABELLED: Many low-grade gliomas (World Health Organization grade II) respond to chemotherapy. Cerebral blood flow (CBF) and microvessel density may be critical for drug delivery. We used PET with (18)F-fluoro-ethyl-l-tyrosine (FET) to measure the spatial distribution of the amino acid carrier, which is located at the brain capillaries, and (15)O-H(2)O to measure tumor CBF.
METHODS: Seventeen patients with low-grade glioma were studied. Region-of-interest (ROI) analysis was used to quantify tumor tracer uptake, which was normalized to cerebellar uptake (tumor-to-cerebellum ratio). "Active" tumor was defined as tumor having a radioactivity concentration that was at least 110% of the cerebellar activity. This threshold provided measures of active tumor volume, global and peak tumor CBF, and (18)F-FET uptake. Trace ROIs were applied to create voxelwise profiles of CBF and (18)F-FET uptake across tumor and brain. Standard MRI sequences were used for spatial correlations.
RESULTS: Fourteen of 17 tumors showed increased global CBF and (18)F-FET uptake. Active tumor volumes ranged between 3 and 270 cm(3) for (18)F-FET and between 1 and 41 cm(3) for CBF. Global (18)F-FET uptake in tumors corresponded to CBF increases (Spearman rank rho = 0.771, P < 0.01). The volumes of increased CBF and (18)F-FET uptake spatially coincided and were also correlated (rho = 0.944, P < 0.01). Trace ROIs showed that irrespective of increased (18)F-FET uptake at the tumor periphery, CBF increases were more confined to the tumor center. Within individual tumors, spatial heterogeneity was present. Particular tumors infiltrating the corpus callosum showed low CBF and (18)F-FET uptake in this tumor region. The patterns observed with PET were not reflected on MRI of the tumors, all of which presented as homogeneous non-gadolinium-enhancing lesions.
CONCLUSION: Low-grade gliomas are heterogeneous tumors with regard to the distribution of amino acid uptake and CBF. Both are coupled in the tumor center. At the tumor periphery, where tumor infiltration of surrounding brain occurs, CBF may be low irrespective of increased (18)F-FET uptake. An ongoing study is investigating the effect of chemotherapy on these observations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17574979     DOI: 10.2967/jnumed.106.038489

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  17 in total

1.  Response to "reply to [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma" by Hutterer et al.

Authors:  Markus Hutterer; Martha Nowosielski; Daniel Putzer; Christian la Fougère; Irene J Virgolini; Andreas H Jacobs; Günther Stockhammer
Journal:  Neuro Oncol       Date:  2013-06-19       Impact factor: 12.300

Review 2.  Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours.

Authors:  G Thompson; S J Mills; D J Coope; J P B O'Connor; A Jackson
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

3.  Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas.

Authors:  M Kunz; N Thon; S Eigenbrod; C Hartmann; R Egensperger; J Herms; J Geisler; C la Fougere; J Lutz; J Linn; S Kreth; A von Deimling; J C Tonn; H A Kretzschmar; G Pöpperl; F W Kreth
Journal:  Neuro Oncol       Date:  2011-02-03       Impact factor: 12.300

4.  Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas.

Authors:  Nathalie L Jansen; Christoph Schwartz; Vera Graute; Sabina Eigenbrod; Jürgen Lutz; Rupert Egensperger; Gabriele Pöpperl; Hans A Kretzschmar; Paul Cumming; Peter Bartenstein; Jörg-Christian Tonn; Friedrich-Wilhelm Kreth; Christian la Fougère; Niklas Thon
Journal:  Neuro Oncol       Date:  2012-10-22       Impact factor: 12.300

5.  Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas.

Authors:  Ulrich Roelcke; Matthias T Wyss; Martha Nowosielski; Roberta Rudà; Patrick Roth; Silvia Hofer; Norbert Galldiks; Flavio Crippa; Michael Weller; Riccardo Soffietti
Journal:  Neuro Oncol       Date:  2015-11-17       Impact factor: 12.300

6.  Early metabolic responses in temozolomide treated low-grade glioma patients.

Authors:  Matthias Wyss; Silvia Hofer; Matthias Bruehlmeier; Martin Hefti; Catrina Uhlmann; Esther Bärtschi; Ulrich Wolf Buettner; Ulrich Roelcke
Journal:  J Neurooncol       Date:  2009-04-18       Impact factor: 4.130

Review 7.  When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET?

Authors:  Gang Cheng; Drew A Torigian; Hongming Zhuang; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-30       Impact factor: 9.236

8.  Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas.

Authors:  Mathias Kunz; Nathalie Lisa Albert; Marcus Unterrainer; Christian la Fougere; Rupert Egensperger; Ulrich Schüller; Juergen Lutz; Simone Kreth; Jörg-Christian Tonn; Friedrich-Wilhelm Kreth; Niklas Thon
Journal:  Neuro Oncol       Date:  2019-02-14       Impact factor: 12.300

9.  Comparison of heterogeneity quantification algorithms for brain SPECT perfusion images.

Authors:  Romain Modzelewski; Elise Janvresse; Thierry de la Rue; Pierre Vera
Journal:  EJNMMI Res       Date:  2012-07-20       Impact factor: 3.138

Review 10.  Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response.

Authors:  Tong Fu; Lei-Jie Dai; Song-Yang Wu; Yi Xiao; Ding Ma; Yi-Zhou Jiang; Zhi-Ming Shao
Journal:  J Hematol Oncol       Date:  2021-06-25       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.